BMY vs. ABBV

In the year-to-date period, BMY achieves a -13.45% return, which is significantly lower than ABBV's 6.67% return. Over the past 10 years, BMY has underperformed ABBV with an annualized return of 0.27%, while ABBV has yielded a comparatively higher 15.75% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and AbbVie Inc. (ABBV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current BMY Sharpe Ratio is 0.08, which is lower than the ABBV Sharpe Ratio of 0.51. The chart below compares the historical Sharpe Ratios of BMY and ABBV, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

BMY's dividend yield for the trailing twelve months is around 5.09%, more than ABBV's 3.43% yield.

The maximum BMY drawdown since its inception was -70.62%, which is greater than ABBV's maximum drawdown of -45.09%. Use the drawdown chart below to compare losses from any high point for BMY and ABBV. For additional features, visit the drawdowns tool.

The current volatility for Bristol-Myers Squibb Company (BMY) is 9.92%, while AbbVie Inc. (ABBV) has a volatility of 12.85%. This indicates that BMY experiences smaller price fluctuations and is considered to be less risky than ABBV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Bristol-Myers Squibb Company and AbbVie Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.